Paris-based Wandercraft, a company focused on self-balancing robotic mobility systems, has raised $75M (nearly €65.37M) in its Series D funding round.
Key investors include Renault Group, PSIM fund – managed on behalf of the French State by Bpifrance, Teampact Ventures, and Quadrant Management. New investors include LBO France, XAnge, Cemag Invest, Martagon Capital, and AG2R LA MONDIALE.
Wandercraft’s Series D funding comes as the company grows its presence in clinical, consumer, and industrial robotics. The round follows a period of revenue growth and US expansion, driven by its earlier $45M Series C raise.
Building robotic systems for movement and mobility
Founded in 2012, Wandercraft develops self-balancing, AI-powered robotic systems focused on mobility. Its exoskeleton, Atalante X, supports people with disabilities and is used in over 100 rehabilitation centres across four continents, helping users take more than a million steps each month.
The company’s systems are based on over ten years of data and a proprietary neural network trained on billions of steps. Wandercraft is now moving beyond clinical applications with Eve, a personal-use exoskeleton designed to help wheelchair users stand and walk in daily environments.
The French company is also introducing the Calvin line of autonomous humanoid robots for industrial and care-related tasks. With over 30 patents, the company continues to develop robotic systems aimed at expanding physical mobility and support in various settings.
Capital utilisation
Wandercraft will use the funds to support several initiatives. These include launching Eve, a self-balancing personal exoskeleton by 2026; expanding the clinical rollout of its rehabilitation system, Atalante X; and developing and deploying Calvin-40, its humanoid robot.
Matthieu Masselin, CEO and co-founder of Wandercraft, says, “The momentum we’ve achieved over the past few years is extraordinary. We’ve expanded globally, launched pivotal clinical trials, readied the commercialisation of Eve, our personal exoskeleton, and entered a landmark partnership with Renault.”
“This funding allows us to continue our mission of transforming how people live, move, and work across rehabilitation, home environments, and soon on factory floors.”
Partnership with Renault Group
Wandercraft has announced a strategic partnership with Renault Group, which now holds a minority stake in the company. The partnership allows Wandercraft to tap into Renault’s manufacturing capabilities to scale production of exoskeletons and industrial robots.
Renault also becomes the first commercial partner and customer of Calvin-40, Wandercraft’s humanoid robot developed in 40 days.
Calvin-40 is designed for physically demanding industrial tasks and is the first humanoid robot developed by a European company. Its development used Wandercraft’s internal robotics platform and NVIDIA Isaac technologies, including the NVIDIA Isaac GR00T N1 foundation model and the NVIDIA Jetson edge AI platform.
Paul-François Fournier, Executive Director of Bpifrance Innovation, says, “We are delighted to renew our support for Wandercraft, which has been supported by Bpifrance since 2017.”
“This D Series, alongside Renault Group, will enable the company to accelerate the industrial deployment of its unique robotics technology and make the Eve exoskeleton accessible to as many people as possible. Access to health and mobility for all is indeed a strategic focus of Bpifrance and France 2030.”
Milestones in robotic mobility and clinical deployment
Wandercraft continues its work on AI-powered, self-balancing robotic systems that support upright movement without crutches or walkers. The company’s technology has been refined through extensive simulation and real-world steps.
It received FDA clearance for its Atalante X exoskeleton for stroke rehabilitation, followed by a second clearance within one year. Atalante X is now in use at over 100 hospitals and rehabilitation centres worldwide.
The company also launched the first clinical trial of a personal exoskeleton, Eve, intended for home and community use by people with severe mobility challenges.
Over 20 clinical studies have examined Wandercraft’s systems, reporting gains in walking speed, balance, and postural control. To date, 2,500 users have taken over 14 million steps using its devices.
Wandercraft also opened “Walk in New York”, a dedicated centre offering regular exoskeleton sessions for individuals with mobility impairments. Located at the Cure healthcare campus in New York City, the site also serves as Wandercraft’s US base and the future regional hub for Eve.
01
These are the top UK-based PR agencies for startups and scale-ups in 2025